Clinical trials: Major Depression Disorder
Major Depressive Disorder, Recurrent, Unspecified
Multiple Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY03005
Objectives To evaluate the safety and tolerability of escalating multiple oral doses of LY03005 in healthy subjects. To characterize the pharmacokinetics of escalating multiple oral doses of LY03005.
- Trial name
- NCT02271412
- Testing
- LY03005
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Major Depressive Disorder
Intradermal Acupuncture Versus Sham Acupuncture and SSRI for Treating Adolescents With Major Depressive Disorder
Major depressive disorder (MDD) is a prevalent mental illness characterised by influencing the health and quality of life of patients，often manifesting in individuals under the age of 18.
- Trial name
- NCT05832619
- Testing
- SSRI, SIA, AIA
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Xiaomei Shao
Major Depression
Secondary Prevention of Depression Through Group-based ACT-Therapy Preceded by an Experimental ABM-Procedure
Depression (major depressive disorder; MDD) is a very common mental disorder. Research suggests that individuals with prior depressive episodes have a risk of the relapse or recurrence of MDD.
- Trial name
- NCT02648165
- Testing
- Attention Bias Modification, Acceptance and Commitment Therapy
- Where
- 2 sites in Norway
- Volunteers
- 224 people
- Sponsor
- Sorlandet Hospital HF
Depressive Disorder, Major
Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD)
Multicenter, open-label, long-term extended access treatment protocol in adult patients with a primary diagnosis of MDD.
- Trial name
- NCT03668600
- Testing
- Rapastinel
- Where
- 74 sites in United States
- Volunteers
- 230 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Posttraumatic Stress Disorder, Major Depressive Disorder
Risk and Resiliency Factors in the RCMP: A Prospective Investigation
The Royal Canadian Mounted Police (RCMP), like all public safety personnel (PSP), are frequently exposed to potentially psychologically traumatic events that contribute to posttraumatic stress injuries (PTSI).
- Conditions
- Posttraumatic Stress Disorder, Major Depressive Disorder, Panic Disorder, Generalized Anxiety Disorder
- Trial name
- NCT05527509
- Testing
- Emotional Resilience Skills Training (ERST), Active Monitoring
- Where
- Canada
- Volunteers
- 960 people, healthy volunteers welcome
- Sponsor
- University of Regina
Major Depressive Disorder
Prediction of the Response to a Course of Transcranial Magnetic Stimulation (rTMS) Based on Heart Rate Variability
Changes in heart rate variability following a single session of rTMS will be tested as a predictor of response to a course of 30 rTMS sessions in patients with major depressive disorder (MDD).
- Trial name
- DEP&MOD (NCT06451809)
- Testing
- repetitive transcranial magnetic stimulation
- Where
- 9 sites in France
- Volunteers
- 160 people
- Sponsor
- GCS CIPS
Myasthenia Gravis, Depression
Depressive Tendency and Counseling Outcomes in Thymoma-Associated MG
This study aimed to examine whether baseline depressive tendency independently predicts post-counseling clinical outcomes in patients with thymoma-associated MG.
- Conditions
- Myasthenia Gravis, Depression, Thymoma, Depression and Quality of Life
- Trial name
- NCT07649187
- Testing
- Psychological counseling intervention
- Where
- Taiwan
- Volunteers
- 19 people
- Sponsor
- Ming-Hsing Chang
HIV/AIDS, Clinical Depression
Zaleplon in HIV Patients With Depression
In HIV positive patients with sleep onset insomnia and receiving pharmacologic treatment for comorbid depression, the proposed study aims to evaluate the impact of zaleplon on sleep measures determined by insomnia severity index…
- Trial name
- NCT03489304
- Testing
- Zaleplon
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Pennsylvania
Depression
Cost- Effectiveness and Quality of Life Assessment in Major Depression Disorder
To evaluate the effectiveness of one algorithm for Major Depression Disorder (MDD) using medications available in the Brazilian Public Healthcare System (SUS), and assessment of the quality of life of these patients.
- Trial name
- NCT02901249
- Testing
- sertraline, Nortriptyline, Lithium
- Volunteers
- 68 people
- Sponsor
- Federal University of Rio Grande do Sul
Depression, Treatment Resistant Depression
Mindfulness Engaged Neurostimulation for Depression (MEND II)
Repetitive Transcranial Magnetic stimulation (rTMS) is an FDA-approved therapy for treatment resistant depression (TRD) that involves brief magnetic stimulation pulses on the dorsolateral prefrontal cortex (DLPFC) brain region.
- Conditions
- Depression, Treatment Resistant Depression, Major Depressive Disorder, Depressive Disorder
- Trial name
- NCT07512284
- Testing
- Medi-TBS
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of California, San Diego
Major Depressive Disorder
Non-Inferiority RCT Comparing Online and On-Site CBT in MDDi
In recent years, Cognitive Behavioral Therapy has been integrated with mindfulness meditation (CBT-M) following evidence for increased efficacy when modalities are combined.
- Trial name
- NCT04825535
- Testing
- Standard psychiatry and cognitive behavioral online intervention, Standard psychiatry and cognitive behavioural in-person intervention
- Where
- Canada
- Sponsor
- Centre for Addiction and Mental Health
Type2 Diabetes, Major Depressive Disorder
Vortioxetine Monotherapy for Major Depressive Disorder in Type 2 Diabetes
This study will enroll participants who have been diagnosed with type 2 diabetes and are experiencing symptoms of depression. This study will look at an anti-depressant medication called vortioxetine (Trintellix).
- Trial name
- NCT03580967
- Testing
- Vortioxetine
- Where
- United States
- Sponsor
- Todd Doyle
Depression, Unipolar
Intermittent Theta-burst Stimulation for Major Depression: an Intensity-response Study
The United States Food and Drug Administration (FDA) approved intermittent theta-burst stimulation (iTBS) in 2018 as a form of repetitive transcranial magnetic stimulation (rTMS).
- Trial name
- NCT06392867
- Testing
- intermittent theta-burst stimulation (iTBS)
- Where
- Hong Kong
- Volunteers
- 246 people
- Sponsor
- The Hong Kong Polytechnic University
Major Depressive Disorder
Ketamine in the Treatment of Depression
Depressed patients will be offered experimental treatment with a new, potentially fast-acting antidepressant called ketamine while being scanned by magnetic resonance imaging (MRI) to measure the chemical effect of the drug.
- Trial name
- NCT01558063
- Testing
- Ketamine, Saline, Magnetic Resonance Imaging (MRI)
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Columbia University
Major Depression Disorder
Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets Versus Venlafaxine Hydrochloride Sustained-release Tablets in Patients With Major Depression Disorder
The purpose of this study is to evaluate efficacy and safety of toludesvenlafaxine hydrochloride sustained-release tablets in the treatment of major depression disorder compared to venlafaxine hydrochloride sustained-release…
- Trial name
- NCT06278038
- Testing
- Toludesvenlafaxine hydrochloride sustained-release tablets, Venlafaxine hydrochloride sustained-release tablets
- Where
- China
- Volunteers
- 84 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Major Depressive Disorder
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-068)(COMPLETED)
A clinical study to determine the efficacy and safety of an investigational medication (MK0869) in the treatment of depression.
- Trial name
- NCT00035048
- Testing
- aprepitant
- Volunteers
- 540 people
- Sponsor
- Merck Sharp & Dohme LLC
Major Depressive Disorder
Assess the Efficacy and Safety of ASC-01 in Patients With Major Depressive Disorder
To evaluate the efficacy and the safety of ASC-01 (aripiprazole/sertraline combination) compared to sertraline monotherapy in patients with major depressive disorders who have responded incompletely to sertraline monotherapy.
- Trial name
- NCT02046564
- Testing
- ASC-01
- Where
- 29 sites in Australia, Japan and 3 more
- Volunteers
- 412 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Major Depressive Disorder
Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder (VLZ-MD-22)
The purpose of this study is to evaluate the efficacy, safety, and tolerability of vilazodone compared with placebo in pediatric outpatients (7-17 years of age) with major depressive disorder.
- Trial name
- VLZ-MD-22 (NCT02372799)
- Testing
- Vilazodone, Fluoxetine
- Where
- 60 sites in United States, Canada
- Volunteers
- 473 people
- Sponsor
- Forest Laboratories
Major Depressive Disorder
AZD7268 Safety and Tolerability Study
The purpose of this study is to prove the principle that treatment with AZD7268 reduces depressive symptoms in patients with Major Depressive Disorder (MDD) compared with placebo.
- Trial name
- NCT01020799
- Testing
- AZD7268, Escitalopram
- Where
- 17 sites in United States
- Volunteers
- 247 people
- Sponsor
- AstraZeneca
Major Depressive Disorders
N-Acetyl Cysteine Supplementation in Therapy Refractory Major Depressive Disorders
The aim of this study is to evaluate the efficacy of N-acetylcysteine (NAC) add-on to antidepressant medication in treating patients who do not relieve during standard antidepressant treatment for 6 weeks at least.
- Trial name
- NCT02972398
- Testing
- N-acetylcysteine
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Tianjin Anding Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.